Open Access BASE2013

Nifurtimox-Eflornithine Combination Therapy for Second-Stage Gambiense Human African Trypanosomiasis: Medecins Sans Frontieres Experience in the Democratic Republic of the Congo

Alirol, Emilie; Schrumpf, David; Amici Heradi, J; Riedel, Anette Juliane; de Patoul, C; Quere, M; Chappuis, François

Open Access

Abstract

Existing diagnostic and treatment tools for human African trypanosomiasis (HAT) are limited. The recent development of nifurtimox-eflornithine combination therapy (NECT) has brought new hopes for patients in the second stage. While NECT has been rolled out in most endemic countries, safety data are scarce and derive only from clinical trials. The World Health Organization (WHO) coordinates a pharmacovigilance program to collect additional data on NECT safety and efficacy. We report here the results of 18 months of experience of NECT use in treatment centers run by Médecins Sans Frontières in the Democratic Republic of the Congo (DRC).

Report Issue

If you have problems with the access to a found title, you can use this form to contact us. You can also use this form to write to us if you have noticed any errors in the title display.